Qiang Li embarks on a Ph.D. journey to develop lung fibrosis on a chip
Meet Qiang Li: a member of our team and a recent graduate from the Master’s program at Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences. With a specialization in cardiovascular physiology, Qiang has been an invaluable addition to our team as he has been working on developing an in-vitro lung model using human cell lines.
The development of this in-vitro lung model is of great significance in the field of cardiovascular physiology as it could provide a valuable tool for understanding the mechanisms of lung-related cardiovascular diseases such as pulmonary hypertension, heart failure, and more. This model could also be used to test potential treatments for these conditions.
We are thrilled to announce that Qiang will be continuing his academic journey by entering the PhD program at Okayama University. We are confident that Qiang will continue to excel in his research and contribute greatly to the field of cardiovascular physiology.
At Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Qiang will have access to state-of-the-art facilities and resources that will enable him to further his research and make significant contributions to the field. We look forward to seeing the progress and developments that will emerge from his PhD research.
As a team, we are proud to have Qiang as one of our own and we are excited to see what the future holds for him. We have no doubt that he will continue to make significant contributions to the field of cardiovascular physiology, and we wish him all the best as he embarks on his PhD journey at Okayama University.
Related: Lab member Chen Wang receives Ph.D. and starts her scientific career
Related: MEXT-sponsored research student joined cardiovascular physiology lab
* * *
Takahashi Lab at Okayama University uses principles of physiology, cellular and molecular biology, and biophysics. The purpose of the lab is to develop science and medicine by unveiling the mechanisms of diseases through collaborations with scientists, epidemiologists, and corporate alliances. The alliance includes Harvard University, Boston University, Texas A&M University, and PD Aerospace, Ltd.